Andrew D. Seidman, MD

Andrew D. Seidman, MD

Medical Oncologist

Titles

Attending Physician

Clinical Expertise

Breast Cancer

Share

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Monday through Friday, 8:00 a.m. to 6:00 p.m., (Eastern time)
Accepted Insurance Providers

Dr. Seidman accepts the following list of insurance providers. Select your insurance provider to see more details.

Aetna

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (City of NY retirees only, starting 7/1/23)

Payor Type:
In Network Coverage Type(s): PPO

Blue Cross Blue Shield Federal Employee Program

Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO

Blue Cross Blue Shield New York

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS

Blue Cross Health Plus

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Carrum Health

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

Cigna

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Connecticare

Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO

Emblem

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Emblem Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Emblem Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO

Empire Blue Cross Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO, DSN

Empire Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Fidelis

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO

Fidelis Managed Medicaid & HARP

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Fidelis Medicare Advantage

Payor Type:
In Network Coverage Type(s): HMO

First Health

Payor Type:
In Network Coverage Type(s): PPO

Healthfirst

Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS

Healthfirst Managed Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Healthfirst Medicare Advantage

Payor Type:
In Network Coverage Type(s): HMO, PPO

Healthsmart

Payor Type: Commercial
In Network Coverage Type(s): PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

Payor Type: Commercial
In Network Coverage Type(s): HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO

Husky CT Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Magnacare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO

Medicare Part A&B (traditional Medicare)

Payor Type:
In Network Coverage Type(s): Federal Government

Multiplan/Beech Street/PHCS

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

MVP

Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP

Non-Participating Plans with Out of Network Benefits

Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

Payor Type:
In Network Coverage Type(s): TBD

Oscar

Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO

Oxford

Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO

Qualcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Straight NJ Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Straight NY Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Tricare

Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO

UMR

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS

United Healthcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

World Trade Center Health Program (WTC)

Payor Type: Commercial
In Network Coverage Type(s): State Government

Contact and Location

Locations map
Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.

See all locations

About Me

Education

MD, Hahnemann University School of Medicine

Residencies

Internal Medicine - Pennsylvania Hospital

Fellowships

Medical Oncology/Hematology - Memorial Sloan Kettering Cancer Center

Board Certifications

Internal Medicine; Medical Oncology

I am an experienced medical oncologist who has spent three decades caring for people with breast cancer. I specialize in treating all subtypes and stages of breast cancer, from the earliest to the most advanced stages of the disease. I have special expertise in the understanding and treatment of breast cancer that has metastasized (spread) to the brain, a condition that has historically been managed primarily by radiation oncologists and neurosurgeons.

I typically see more than 1,000 patients each year, both remotely and in person. The pandemic has taught us that we can treat patients’ disease and improve well-being both ways, but I much prefer to see patients in person.

Read more

Patients and their loved ones are naturally concerned about how breast cancer will affect their survival and quality of life. The large amount of information available on the internet often leads people to feel overwhelmed and confused. My goal is to provide them with expert, evidence-based guidance in terms of diagnosis, prognosis, and treatment, along with humane and compassionate care. I trust that this, along with the tremendously skilled team that works with me, reassures patients and leaves them feeling hopeful, optimistic, realistic, and secure in the knowledge that they are in capable and caring hands here at Memorial Sloan Kettering Cancer Center (MSK).

For me, oncology, more than any other specialty, demands a deep understanding of physiology, genetics/genomics, and humanity — and represents a great unmet need. Meaningful and rewarding patient experiences during my residency in internal medicine, an early exposure to outpatient medical oncology practice, and strong role models were important factors in my decision to become an oncologist.

Outcomes for people with breast cancer have steadily improved over the past 30 years, thanks to a tremendous increase in the understanding of underlying biology that has informed advances in surgical, medical, and radiation treatment. As the last chemotherapy drug for breast cancer was introduced well over a decade ago, there has been a shift away from conventional toxic chemotherapy to targeted therapies, which generally have fewer side effects. It has been exciting for me to be a part of this movement by designing and leading phase 1, 2, and 3 clinical trials.

My research has focused on studying new chemotherapeutic agents and targeted drugs for the treatment of metastatic breast cancer. Over the past decade, I have worked to identify better medical therapies to improve outcomes for people with breast cancer metastasis to the brain. I continue to lead and engage in interdisciplinary research in this area with my colleagues at MSK and beyond. These ongoing efforts will likely lead to changes in the way patients are treated in coming years.

Overall, I subscribe to a “work hard, play hard” philosophy! In my spare time, I enjoy biking, hiking, skiing, gardening, baking, and reading. I recently organized a book club that meets every three months, which has been especially enjoyable. I cherish the time I get to spend with my family and look forward to being able to travel more easily to see the world as the pandemic subsides.

Awards and Honors

  • Castle Connolly: America's Top Doctors (2023)

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. I work closely with nurse practitioner Rachel Motzer. We combine our expertise to provide comprehensive care to our patients at every step of their cancer journey.

See all Breast Medicine Service doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Morikawa A, Grkovski M, Patil S, Jhaveri KL, Tang KL, Humm JL, Holodny A, Beal K, Schöder H, Seidman AD. A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging. Breast Cancer Res Treat 2021. 

Seidman AD, Maues J, Tomlin T, Bhatnagar V, Beaver JA. The evolution of clinical trials in metastatic breast cancer: Design features and endpoints that matter. Am Soc Clin Oncol Educ Book 40:1-11, 2020.  

Tripathy D, Cortes J, Seidman AD, et al. ATTAIN: Etirinotecan Pegol Versus Treatment of Physician’s Choice in Patients with Breast Cancer and Brain Metastases. Future Oncology 15(19):2211-25, 2019. 

Seidman AD, Bordeleau L, Fehrenbacher L et al. National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. J Clin Oncol 36(32):3259-68, 2018. Special Article 

Morikawa A, Patil S, Diab A, Yang J, Hudis CA, McArthur HL, Beal K, Seidman AD. Characteristics and prognostic factors for patients with HER2-overexpressing breast cancer with brain metastasis in the era of HER-2 targeted therapy: An argument for earlier detection. Clin Breast Cancer 18(5):353-361, 2018. 

Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy CG, Lockman PR, Simmons A, Weil RJ, Tabar V, Steeg PS, Smith QR, Seidman AD. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro-Oncol 17(2):289-95, 2015.

Brogi E, Murphy CG, Johnson ML, Conlin AK, Hsu M, Patil S, Akram M, Nehhozina T, Jhaveri KL, Hudis CA, Seidman AD.  Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays.  Ann Oncol 22(12):2597-603, 2011.

Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C.  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.  J Clin Oncol 26(10):1642-1649, 2008. 

Publications on PubMed

Visit PubMed for a full listing of Dr. Seidman’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Andrew D. Seidman discloses the following relationships and financial interests:

  • Affinia Therapeutics, Inc.
    Provision of Services
  • AstraZeneca
    Provision of Services
  • BeyondSpring
    Provision of Services
  • Cancer Expert Now, Inc.
    Provision of Services
  • Eli Lilly and Company
    Provision of Services
  • G1 Therapeutics
    Provision of Services
  • Genentech
    Provision of Services
  • Genomic Health, Inc.
    Provision of Services
  • Gilead Pharmaceutical
    Provision of Services
  • Hackensack University Medical Center
    Provision of Services
  • Immunomedics
    Provision of Services
  • Incyte
    Provision of Services
  • MJH Associates
    Provision of Services
  • Novartis
    Provision of Services
  • Parexel International
    Provision of Services
  • Pfizer, Inc.
    Provision of Services
  • myMedEd, Inc.
    Provision of Services

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures